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Abstract
Background: The bone conduction implant (BCI) is an active 
transcutaneous bone conduction device where the trans-
ducer has direct contact to the bone, and the skin is intact. 
Sixteen patients have been implanted with the BCI with a 
planned follow-up of 5 years. This study reports on hearing, 
quality of life, and objective measures up to 36 months of 
follow-up in 10 patients. Method: Repeated measures were 
performed at fitting and after 1, 3, 6, 12, and 36 months in-
cluding sound field warble tone thresholds, speech recogni-
tion thresholds in quiet, speech recognition score in noise, 
and speech-to-noise thresholds for 50% correct words with 
adaptive noise. Three quality of life questionnaires were 
used to capture the benefit from the intervention, apprecia-
tion from different listening situations, and the ability to in-
teract with other people when using the BCI. The results 
were compared to the unaided situation and a Ponto Pro 
Power on a soft band. The implant functionality was mea-
sured by nasal sound pressure, and the retention force from 
the audio processor against the skin was measured using a 
specially designed audio processor and a force gauge. Re-
sults: Audiometry and quality of life questionnaires using 
the BCI or the Ponto Pro Power on a soft band were signifi-
cantly improved compared to the unaided situation and the 
results were statistically supported. There was generally no 
significant difference between the two devices. The nasal 
sound pressure remained stable over the study period and 
the force on the skin from the audio processor was 0.71 ± 
0.22 N (mean ± 1 SD). Conclusion: The BCI improves the 
hearing ability for tones and speech perception in quiet and 
in noise for the indicated patients. The results are stable over 
a 3-year period, and the patients subjectively report a ben-
eficial experience from using the BCI. The transducer perfor-
mance and contact to the bone is unchanged over time, and 
the skin area under the audio processor remains without 
complications during the 3-year follow-up.
© 2020 The Author(s)
Published by S. Karger AG, Basel
Background
Implantable bone conduction devices (BCDs) are gain-
ing increasing interest as a rehabilitative option for patients 
with conductive or mixed hearing loss and for patients with 
This is an Open Access article licensed under the Creative Commons 
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single-sided deafness. For almost 40 years, the percutane-
ous bone-anchored hearing aid has been a common choice 
of rehabilitation for these patient groups. In the percutane-
ous solution, the skin is penetrated by a titanium abutment 
(Ponto, Oticon Medical, Askim, Sweden, or Baha, Cochlear 
BAS, Mölnlycke, Sweden). Complications, such as skin in-
flammation or loss of the titanium screw implant, have 
driven the development towards implantable BCDs with an 
intact skin solution. The obvious advantage with an intact 
skin solution compared to the percutaneous solution is the 
possible decrease in skin complications. The major disad-
vantage is that implantable devices with an intact skin solu-
tion require a more extensive surgical procedure. Also, it 
becomes more complicated to perform magnetic resonance 
imaging (MRI) due to magnetically induced forces, and that 
the images of the brain will be distorted in regions close to 
the implant [Jansson et al., 2015]. 
Today, the implantable BCDs are divided into two 
main groups: direct drive systems, where the transducer 
has direct contact to the bone, and skin drive systems, 
where the transducer is attached onto the skin [Reinfeldt 
et al., 2015a]. Direct drive systems are also divided into 
percutaneous and active transcutaneous systems, where 
the active transcutaneous systems imply that the trans-
ducer is implanted under intact skin. 
The bone conduction implant (BCI) is an active trans-
cutaneous BCD and consists of an implanted part includ-
ing the receiver coil, the retention magnet and the trans-
ducer, and an audio processor, which is retained on the 
skin by magnetic force [Hakansson et al., 2010; Taghavi 
et al., 2015] (Fig. 1). 
Since 2012, 16 patients have been implanted with the 
BCI and enrolled in a clinical study with a protocol fol-
low-up time of 5 years. Report of the first patient who 
received a BCI, and reports of the first 6 patients in a 
6-month follow-up, have previously been published [Eeg-
Olofsson et al., 2014; Reinfeldt et al., 2015b]. In summary, 
the audiological outcomes in terms of tone audiometry 
and speech audiometry in quiet and in noise were signif-
icantly improved compared to the unaided situation and 
similar or better compared to a Ponto Pro Power (Oticon 
Medical, Askim, Sweden) on a soft band. Quality of life 
questionnaires also showed similar or improved results 
compared to the soft band device. The BCI surgery was 
regarded as being easy by the surgeon performing all sur-
gical procedures in the current study. No serious adverse 
events occurred. The BCI has furthermore been tested in 
a 1.5-tesla MRI resulting in a 1-dB deterioration of the 
maximum power output and 5% loss of magnetic force of 
the retention magnet [Jansson et al., 2015]. On the MRI 
image, half of the brain was heavily distorted, but the dis-
tortion was expected and in the same range as for the 
Bonebridge (Med El, Innsbruck, Austria) and the Sopho-
no (Medtronic, Dublin, Ireland). To test the long-term 
functionality, a test BCI has been exposed to continuous 
sounds 24 h a day, showing no signs of performance de-
terioration up to an estimated user time of 26 years (12 h 
per day) [Fredén Jansson et al., 2019].
Objectives
The aim of this study is to report on audiometric re-
sults and patient-reported outcome measures from qual-
ity of life questionnaires for the first 10 patients at the 
3-year follow-up. Furthermore, an analysis of the change 
in rehabilitation effect over time for these 10 patients is 
reported. 
Materials and Methods
Subjects
Sixteen subjects have been included in the clinical trial of the 
BCI, 7 males and 9 females. In this study, results for the first 10 
subjects, 5 males and 5 females, are given from their first 3 years 
with the BCI. Type of hearing loss, gender, implant side, and age 
at implantation of all subjects are shown in Table 1. The inclusion 
criteria for the study were: (1) unilateral or bilateral conductive 
hearing loss with an air-bone gap of at least 20 dB (average over 
500, 1,000, 2,000, and 4,000 Hz); (2) pure tone average bone con-
duction (PTA4,BC) of 30 dB HL (average over 500, 1,000, 2,000 and 
4,000 Hz) or better; (3) To either reject or be unable to use a con-
ventional air conduction hearing aid; (4) to be accessible for mul-
tiple follow-up visits according to the protocol and be motivated 
to be one of the first subjects using the BCI.
Audio processor
Transducer
Coil Retention magnet
Fig. 1. Complete system of the bone conduction implant (BCI) 
showing the implanted part and the audio processor.
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Overall Procedure
After inclusion of a patient, a date for BCI surgery was decided. 
Before the BCI surgery, a reference device on a soft band was fitted 
and used for 4 weeks followed by audiometric tests and quality of 
life questionnaires. The same tests and questionnaires were later 
used for the implanted BCI.
The BCI was implanted under general anesthesia. A detailed 
description of the surgical procedure can be found in previously 
published studies [Eeg-Olofsson et al., 2013; Reinfeldt et al., 
2015b].
One month after surgery, fitting of the BCI audio processor 
took place. On this occasion and at all follow-up visits, audiomet-
ric tests and objective measures were performed. The follow-up 
visits took place 1, 3, 6, 12, and 36 months after fitting. The audio-
metric test order was randomized at all follow-up visits for each 
patient to minimize the order effect; also the order of the blocks 
(unaided-aided) was varied. The different speech lists for each 
speech test were randomized to be evenly spread at both the un-
aided and the aided test situation.
The Abbreviated Profile of Hearing Aid Benefit (APHAB) and 
the Glasgow Benefit Inventory (GBI) questionnaires were com-
pleted by the patients after using the reference device for 1 month, 
and 6, 12, and 36 months after the BCI fitting. At the 36 months 
visits, the International Outcome Inventory of Hearing Aids (IOI-
HA) was added. 
Reference Device
A reference device, Ponto Pro Power (Ponto, Oticon Medical, 
Askim, Sweden) on a soft band, hereafter referred to as the refer-
ence device, was fitted using in-situ thresholds, including skin 
compensation of 10-dB higher gain in the high frequency range. 
The reference device was individually fitted for each patient with 
one general program, the algorithm NAL-NL1 in the software 
Genie Medical (Oticon Medical, Askim, Sweden), using omnidi-
rectional microphones, and all automatic functions, such as feed-
back manager and noise manager, turned off. The generic reso-
nance frequency at approximately 750 Hz that appears in the di-
rect drive percutaneous application is electronically damped in 
the Ponto device, and it was not possible to turn this dampening 
effect off. The reference device was used for 4 weeks and evalu-
ated with audiometric tests and two questionnaires, APHAB and 
GBI. 
Fitting of the BCI
For fitting of the audio processor, a computer-based software 
(On Semiconductor, Phoenix, AZ, USA) was used. No specific fit-
ting algorithms taking the subjects’ hearing thresholds into ac-
count have been developed so far. Individual adjustments were 
made at fitting, and if necessary, more adjustments were made at 
follow-up visits. The BCI audio processor has six pre-set program 
options, but after some time, it turned out that mainly the first 
program (Pr 1) was used, and that the second program (Pr 2) was 
used occasionally in noisy environments. In Pr 1, the most pre-
ferred settings regarding frequency shaping and volume control 
were implemented. Those settings were determined during the ini-
tial fitting of the device generally based on an assumed target giv-
ing maximum linear gain over all frequencies while still allowing 
a reasonably large headroom before saturation at 70 dB SPL input 
sound level. This headroom was set to be larger at lower frequen-
cies (approx. 20 dB below 1,000 Hz) and smaller at higher frequen-
cies (approx. 10 dB above 1,000 Hz) in order not to distort speech 
level sounds. The patients’ audiograms and their in-situ thresholds 
obtained with the reference device were also used for determining 
frequency-specific adjustments. Finally, the preferred volume con-
trol setting was decided and pre-set for start-up. In the initial fit-
ting, as well as in later follow-up visits, adjustments were made 
based on an interaction with the patients and their experience. In 
some patients, compression was later introduced to reduce the 
negative influence of hearing their own voice. In Pr 2, all settings 
were based on Pr 1, but with a general reduction of the high fre-
quency gain in order to offer a more comfortable sound in noisy 
environments. For all audiometric tests in this clinical study, Pr 1 
and the preferred volume control setting were used.
Audiometric Tests
The audiometry was done in a sound insulated test room of 16 
m3, and the equipment was calibrated according to standard pro-
cedures. All audiometric tests were performed in a sound field, 
where all signals (tones, speech and noise) were played from a 
loudspeaker 1 m in front of the patient. The methods used were (a) 
warble tone thresholds, (b) speech recognition score (SRS) in noise 
with phonemically balanced word lists at 4 dB higher level than the 
noise, measured at 63 dB SPL (ISO: 8253-3 [2012]), (c) speech rec-
ognition thresholds (SRT) in quiet using Swedish spondees ac-
cording to ISO 8253-3 [2012], and (d) signal-to-noise ratio thresh-
Table 1. Type of hearing loss, gender, implant side, and age at implantation described for each patient
Patient Hearing loss Gender Implant side Age at implantation
of BCI, years
1 unilateral mixed loss F R 42
2 bilateral conduction loss M L 48
3 unilateral conduction loss M R 18
4 bilateral conduction loss F L 67
5 bilateral mixed loss F R 48
6 bilateral conduction loss M L 49
7 unilateral conduction loss M L 20
8 bilateral conduction loss M L 49
9 unilateral conduction loss F L 20
10 bilateral conduction/mixed loss F L 21
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olds (SNR thresholds) with five-word Hagerman sentences at a 
fixed level of 63 dB SPL and adaptive noise level to reach 50% 
speech intelligibility [Hagerman and Kinnefors, 1995]. The speech 
and noise levels were monitored using an AC40 audiometer (In-
teracoustics AS, Assens, Denmark). 
During all measurements, blocking of the non-test ear with an 
earplug (E-A-R Classic Soft) and an earmuff (Peltor, 3M Svenska 
AB, Sollentuna, Sweden) was applied for all subjects with contra-
lateral hearing thresholds better than or similar to the thresholds 
of the implanted ear. The purpose of blocking the non-test ear is 
to attenuate the air conducted sound, while letting the bone-con-
ducted sound be perceived by both cochleae, like in real-life situa-
tions. The earplug was inserted deep in the ear canal to minimize 
the occlusion effect [Stenfelt and Reinfeldt, 2007].
Patient-Related Outcome Measures
The questionnaires used were APHAB, GBI, and IOI-HA. 
APHAB focuses on the difference between unaided and aided 
condition and has four subscales: Ease of Communication (EC), 
Reverberation (RV), Background Noise (BN), and Aversiveness of 
sounds (AV) [Cox and Alexander, 1995]. The first three subscales 
EC, RV, and BN address speech understanding in various everyday 
environments. The fourth subscale, AV, quantifies negative reac-
tions to environmental sounds. APHAB produces scores in per-
centage between 0 to 100% for both aided and unaided perfor-
mance as well as hearing aid benefit. A lower score represents a 
more beneficial situation. However, the score will be presented as 
an improvement compared to the unaided condition. The unaided 
condition is asked for before surgery in comparison with the refer-
ence device, and after surgery at every follow-up visit in compari-
son with the BCI. 
The GBI questionnaire measures patient benefit in general as a 
change in health status after an otorhinolaryngological surgical or 
medical intervention [Robinson et al., 1996]. GBI has three subdo-
mains: general, social, and physical benefit. The responses are 
scaled and averaged to give a score between –100 and +100, where 
everything above 0, which represents the unaided condition, indi-
cates a benefit from the intervention. The purpose of the GBI is to 
show if there is a general benefit or a change in health status after 
a surgical or medical intervention. 
IOI-HA was used only at the 36-month follow-up visit. IOI-
HA is a seven-item questionnaire with issues that concern aspects 
of hearing as daily use of the hearing aid, benefit, satisfaction, par-
ticipation difficulties, impact on others and quality of life. The 
main goal of the IOI-HA was to develop a short questionnaire 
suitable for translation into different languages and for compari-
son of the different results between countries [Cox and Alexander, 
2002; Kramer et al., 2002]. The focus of IOI-HA is primarily on 
items associated with the wearer’s experience of using the hearing 
aid separated from specific listening situations, and also limita-
tions in daily activities. Thus, it should be used as a complement 
to other subjective measures [Cox and Alexander, 2002]. Cox and 
Alexander [2002] identified two factors where items “Use time,” 
“Benefit,” “Satisfaction,” and “Quality of life” were clustered into 
Factor 1, while “Residual activity limitation,” “Residual participa-
tion restriction,” and “Impact on others” were clustered into Fac-
tor 2. Patients were also given an extra question concerning how 
many days a week they used their BCI. Low scores signalize not 
sufficient rehabilitation and high scores a successful rehabilita-
tion, although there are no normative data to support either re-
sults. For the item “Hours of daily use” the alternatives are: no use, 
less than 1, 1–4, 4–8 h, and more than 8 h, corresponding to a score 
from 1 to 5.
Objective Measures
Audio Processor Force Attachment to the Skull
At every visit after implantation, the retention force to the im-
plant magnet was measured to make sure that the force was not too 
high for the patient. A reference audio processor was used for these 
measurements, specially designed with the standard magnet strength 
and hooks to attach a force gauge model FG-5000A from Lutron 
Electronic Enterprise co., LTD., China. The retention force was de-
fined as the peak force required to pull the audio processor perpen-
dicular to the skull bone surface until it was released from the head. 
Above 0.7 N, changing to a weaker magnet was considered. If any 
inconvenience or symptoms from a too high retention force were 
noted, i.e. pain, redness or inflammation of the skin area of the audio 
processor, the magnet was changed to a weaker strength.
Nasal Sound Pressure
In order to have functionality verification of the BCI implant 
at surgery, and also to have an objective measure on the implant 
transmission to bone over time, nasal sound pressure (NSP) was 
obtained. At surgery, before closing the wound, and at every 
follow-up visit, an omni-directional microphone (EM-23346, 
Knowles Electronics, Itasca, IL, USA) attached to a probe tube 
within an EAR Classic ear-plug (3M, Maplewood, MN, USA), was 
inserted in the ipsilateral nostril. An amplitude-modulated driver 
stage was developed to drive the inductive link using an Agilent 
35670A (Keysight Technologies, Santa Rosa, CA, USA) as an FFT 
analyzer and speech frequency signal generator, and an Agilent 
33220A (Keysight Technologies) as a carrier frequency and ampli-
tude modulation signal generator. The driver stage was attached to 
the skin like the ordinary audio processor. With the BCI in place 
in direct contact to the bone, vibrations are transmitted through-
out the skull and radiating into all cavities, including the nasal 
cavities, creating a sound pressure whose frequency response was 
measured using the Agilent 35670A in the frequency range of 0.1–
10 kHz. Reinfeldt et al. [2019] provide a more detailed description 
of the NSP layout and calculations.
Data Analysis
The improvement given by the BCI and the reference device in 
warble tone thresholds was calculated as the difference between the 
measurements at the 3-year follow-up visit and the average un-
aided condition. The statistical significance of the improvement at 
each frequency was tested at significance level α < 5% using the 
Wilcoxon signed rank test with the null hypothesis of no difference 
between the aided and the unaided conditions. No correction for 
multiple comparisons was deemed necessary since the tests are in-
tended to identify at which frequencies the improvement differs 
from zero rather than to pairwise compare each frequency. The 
Wilcoxon signed rank test was used also to compare the two aided 
conditions, i.e. BCI compared to the reference device.
Improvements in SRS and SRT were analyzed analogously. 
SNR thresholds were considered only in the aided condition due 
to the fact that it was not possible to measure the unaided condi-
tion at the same speech level for all the patients.
Linear regression analysis was performed in order to study pos-
sible trends over time, and the regression lines coefficients (k) were 
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used as an indication of increasing (k > 0), decreasing (k < 0) or 
stable results (k∼0). Linear models were fitted for each patient, and 
the obtained coefficients were tested with the Wilcoxon signed 
rank test to check for potential group trends. For 2 patients, data 
from one follow-up visit was missing (12 months for patient 3 and 
3 months for patient 6); the regression coefficient in these cases 
was computed based on the remaining available data.
Data analysis was performed with MatLab R2018b (Math-
Works Inc., Natick, MA, USA).
Results
Audiometric Results
Ten patients have completed the 3-year follow-up, and 
in Figure 2, it is shown that the warble tone thresholds at 
the 3-year follow-up for the BCI and the reference device 
provide an average PTA4 (500, 1,000, 2,000, and 4,000 
Hz) improvement of 31.7 dB (median: 31.6 dB, range: 
19.8–42 dB) and 25.4 dB (median: 28.4 dB, range: 8.1–
35.7 dB), respectively, over the unaided condition. The 
Wilcoxon signed rank test shows that the improvement 
is statistically significant (p < 0.05) at all frequencies, ex-
cept at 250 and 8,000 Hz. The improvement calculation 
was based on the average unaided tone threshold of all 
test occasions. There was no change in statistical signifi-
cance when including unaided results only at the 3-year 
follow-up. Comparing the BCI and the reference device, 
the BCI results seem generally better although supported 
by a statistically significant difference only at 750, 2,000, 
and 4,000 Hz.
There is a statistically significant improvement in SRT 
and SRS over the unaided situation for the BCI and for 
the reference device at the 3-year follow-up, as shown in 
Figure 3. Compared to the unaided condition, the average 
improvement with the BCI was 27.5 dB in SRT (median: 
26.6 dB, range: 17.5–41 dB) and 42.6% in SRS (median: 
41%, range: 28–58%). With the reference device, the SRT 
average improvement was 27.2 dB (median: 28.6 dB, 
range: 7.9–37.3 dB), and the SRS was improved by 43.8% 
on average (median: 46%, range: 20–62%).
Nine out of 10 patients showed a better SNR threshold 
with the BCI compared to the reference device (Fig. 3, 
rightmost panel), but according to the Wilcoxon signed 
rank test, there was no statistically significant difference 
between the devices.
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Fig. 2. Mean warble tone threshold improvement of all patients for the BCI together with their average (thick 
solid line) and the average for the reference device (thick dotted line) at 3-year follow-up. Statistically significant 
different results between the BCI and the reference device were found at 250, 750, 2,000, and 4,000 Hz, marked 
with an asterisk.
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Patient-Related Outcome Measures
The results from APHAB (divided in four subscales: 
EC, BN, RV, and AV) are presented as improvement from 
the unaided to the aided condition over time in Figure 4. 
For the subscales EC, BN and RV, there is a statistically 
significant difference between unaided and both the ref-
erence device and the BCI for all follow-up visits, but for 
the subscale AV, the Wilcoxon signed rank test shows no 
statistically significant difference. There was no statisti-
cally significant difference between the reference device 
and the BCI.
Figure 5 presents results for the GBI over time. The 
GBI results show a statistically significant benefit for both 
devices except in physical health for the reference device. 
There was no statistically significant change over the 
3-year follow-up between the BCI and the reference de-
vice.
The questionnaire IOI-HA was used from the 36- 
month follow-up (Fig. 6). The mean score for all ques-
tions was 4.2. In factor 1 (Daily use, Benefit, Satisfaction, 
and Quality of life), the patient score was between 3.9 and 
4.6, and in factor 2 (Residual activity limitation, Restric-
tion in participation, and Impact on others), the patient 
score was between 3.7 and 4.1. The BCI was used 5.6 days 
a week, on average.
To visualize the distribution of responses, Figure 7 
presents the percentage of patient responses to each ques-
tion according to score. 
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Fig. 3. Aided SRT and SRS (left and middle 
boxplots) for the BCI (blue) and the refer-
ence device (pink) compared to the unaid-
ed condition. The boxplot shows the 25–75 
percentiles where the horizontal line is the 
median. Mean is depicted as a green star 
and data points are grey dots. SNR thresh-
olds (right) for each patient are shown as 
blue stars for the BCI and pink stars for the 
reference device. All results in Figure 3 
have been obtained from the 36-month fol-
low-up visit.
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Audio Processor Force Attachment to the Skull and 
NSP
None of the patients had any skin problems related to 
the retention force, although patient 2 changed to a stron-
ger retention magnet at the 3-month follow-up, but 
changed it back again to a weaker magnet at the 12- and 
36-month follow-ups. Patient 4 changed to a weaker 
magnet strength at the 36-month follow-up. The reten-
tion force was found to increase during the first month of 
use in all patients, probably as a result of compression of 
the skin and soft tissues over the retention magnet. The 
average retention force during 3 years of use for all pa-
tients was 0.71 ± 0.22 N (mean ± 1 SD). The average re-
tention force increase during the first month was 0.14 ± 
0.11 N. 
The NSP obtained at surgery generally showed differ-
ent results between the patients. Based on NSP in a pilot 
study on 20 healthy subjects [Shirinkar and Ghoncheh, 
2013], the anticipated frequency response was used to de-
cide whether the implant was considered to be function-
ing and if implant-to-bone contact was considered suffi-
cient, which in this clinical study was the case for all pa-
tients at surgery before closing the wound and at all 
follow-up visits. The results at surgery varied from the 
follow-up measurements in all patients [Reinfeldt et al., 
2019], as can be seen in Figure 8, where the NSP from pa-
tient 4 is shown as an example. In the follow-up NSP mea-
surements, there were large interindividual differences, 
but low intraindividual variability. 
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Fig. 5. GBI scores after using the reference 
device and after using the BCI for 6, 12, and 
36 months. The unaided situation is set to 
0.
Fig. 6. IOI-HA results after using the BCI 
displayed as an average value for the 10 in-
cluded patients. Use, Hours of daily use; 
Ben, Benefit; RAL, Residual activity limita-
tion; Sat, Satisfaction; RPR, Residual par-
ticipation restriction; Ioth, Impact on oth-
ers; QoL, Quality of life.
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Discussion
For the 10 patients who have worn their BCI device for 
3 years, there are no significant changes in unaided BC 
thresholds. On average, audiometric results show a statis-
tically significant advantage with the BCI over the un-
aided situation, and similar or better results compared to 
the reference device. There are some differences over 
time in favor of the BCI compared to the reference device. 
The questionnaires indicate an overall satisfaction with 
the BCI compared to the unaided situation.
Audiometric Results over Time
An important purpose of the audiometric results is to 
clarify if there has been a change in improvement in the 
BCI compared to the unaided situation over time. In Fig-
ure 9, sound field warble tone average improvement (500, 
1,000, 2,000, and 4,000 Hz) is shown for 0-, 1-, 3-, 6-, 12-, 
and 36-month follow-ups. For each patient, a linear mod-
el is fitted, and the obtained slopes are tested with the 
Wilcoxon signed rank test to determine if the trend over 
time at one specific frequency is different from zero. No 
significant trend was detected in any of the four analyzed 
frequencies. In the same way, Figure 10 displays SRT, 
SRS, and SNR thresholds over time. The results are stable, 
and the slopes indicate small individual changes although 
not statistically significant at a group level. 
The intrasubject variations in both tone and speech 
audiometry are generally quite small. The results are in 
every test occasion better for both the BCI and the refer-
ence device compared to the unaided situation. In a more 
detailed scrutiny of the difference between the BCI and 
the reference device, the latter not seldom leads to a better 
result, although the average and median results are in fa-
vor of the BCI, except for the SRS results. It is important 
to emphasize that the reference device results are only 
obtained at one occasion before the BCI surgery, and then 
not repeated. This methodology can imply a higher risk 
of outliers compared to performing repeated measure-
ment during the study period. As always, when obtaining 
results from subjective measures, many factors can affect 
the results. Interestingly, the SRS improvement at the 3 
years’ visit for the BCI is worse compared to the improve-
ment of the reference device. The corresponding result 
for SRT is highly similar, and for SNR thresholds, on the 
contrary, better. The advantage of using more than one 
speech test yields results that can imply a broader under-
standing of the concept of speech perception. There is no 
agreement on which of the tests is the most representative 
of the rehabilitation quality. Therefore, it is of major im-
portance not to draw specific conclusions from rather 
limited differences in speech results when comparing de-
vices within a study, or when comparing devices between 
different studies with similar test batteries. Authors and 
clinicians must acknowledge that these tests are still blunt, 
and results should be interpreted with care. For the cur-
rent study, the audiometric results show a significant im-
provement for the BCI and the reference device com-
pared to the unaided situation, while the comparison be-
tween the BCI and the reference device shows similar 
results.
Quality of Life
Although widely used in Swedish hearing aid research, 
APHAB and GBI are not validated for the Swedish lan-
guage, which is suboptimal from a scientific point of view. 
IOI-HA is validated for the Swedish language. The ques-
tionnaires included in this study are constructed based on 
the aim of the questionnaire and what the constructors 
believe is important to highlight. It is important however 
to be critical about what is missing in the questionnaires. 
To be able to understand what the patient believes is the 
most important issue, a qualitative approach with inter-
views in focus groups or deep interviews with, in this case, 
patients who have undergone a surgical intervention for 
an implantable hearing aid, might be considered. The 
qualitative approach in constructing questionnaires of 
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Fig. 7. Distribution of responses in percent for each IOI-HA item. 
Use, Hours of daily use; Ben, Benefit; RAL, Residual activity limi-
tation; Sat, Satisfaction; RPR, Residual participation restriction; 
Ioth, Impact on others; QoL, Quality of life.
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Fig. 8. Typical NSP (nasal sound pressure) 
results, in this case for patient 4. The thick 
solid blue line represents the measurement 
at surgery, and the six thin dotted lines are 
measurements at follow-up visits, from fit-
ting to 36 months. The average follow-up 
result is shown as a thick solid black line, 
and the average noise floor as a thick dotted 
black line.
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different types is gaining both interest and popularity. All 
tests used in the current study have limitations, which ac-
counts for tone- and speech audiometry, but also for the 
questionnaires. To be able to cover for the weaknesses, 
the authors have included multiple tests for both speech 
tests and questionnaires. Using this methodology, it 
seems reasonable that the conclusions are less affected by 
outliers due to the test itself.
Over time, there are only minor differences in the 
questionnaire scores. APHAB and GBI results show 
that both the BCI and the reference device score statis-
tically significantly better compared to the unaided sit-
uation except for the AV domain in APHAB. Interest-
ingly, in GBI, the reference device shows no significant 
difference compared to the unaided situation in the 
physical health domain. Although not statistically sup-
ported, there is a trend for improved physical benefit 
for the BCI compared to the reference device. The main 
purpose of developing active transcutaneous devices is 
that the transducer is attached directly to the bone with 
intact skin above. It is assumed that the active transcu-
taneous solution can provide both better comfort and 
less skin complications compared to percutaneous and 
skin drive passive transcutaneous solutions. The find-
ing in the GBI physical health domain might support 
this assumption. 
The IOI-HA was only used once in this study, at the 
36-month follow-up. The partition of the results into fac-
tors can be helpful to identify the experience of wearing 
the BCI (factor 1), and the role the BCI plays when inter-
acting with people around the user (factor 2). In this 
study, the scores are regarded as high, above 2 for both 
factors with slightly higher results for factor 1 [Cox and 
Alexander, 2002]. 
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By using all three questionnaires, the authors believe 
that a general satisfaction was captured regarding listen-
ing situations, health status, and benefit for the patients 
alone and in interaction with other people.
Audio Processor Attachment to Skin and Transducer 
Contact to Bone
The NSP allows to verify the implant functionality be-
fore closing the wound and to follow sound transmission 
over time. There is always some uncertainty whether im-
plantable electronics are functioning properly after im-
plantation, and using a tool for verification can eliminate 
risks, time, and costs which will follow from an addition-
al avoidable surgery. Another tool to control the implant 
functionality used in the current BCI study is a battery-
operated audio processor that produces a short melody of 
tones when the implant is functioning properly and has 
good contact to the bone. Schnabl et al. [2014] placed a 
microphone on the forehead in both cadavers and live 
humans and could in that way verify the implant to bone 
contact and the functionality of an implanted Bonebridge 
[Schnabl et al., 2014]. No matter which method is used, a 
verification tool is recommended when doing this kind of 
surgical and audiological intervention. 
The NSP measurement was done in all patients at ev-
ery follow-up visit and confirms that the bone to implant 
contact is intact, even if results from audiological testing 
in some patients vary more than expected. The NSP re-
sults have been consistent in all patients, and the mea-
surement does not seem to be sensitive to, e.g., a swollen 
nasal mucosa, although no such testing has been a param-
eter in the NSP study [Reinfeldt et al., 2019]. The reasons 
for the different results at surgery and at the subsequent 
follow-ups are not known. The situation at surgery when 
a patient is anesthetized and has a tracheal tube in place 
probably comprises the explanation, but the mechanisms 
for the different results are still unknown.
The force of BCI audio processor retention over the im-
plant was on average 0.71 N, which is lower compared to a 
skin drive passive transcutaneous device (e.g., 1.2 N in Co-
chlear Baha Attract) [den Besten et al., 2019]. No adverse 
events from skin inflammation or infection have been re-
ported during the 3-year follow-up period of the BCI. 
Comparison with Other Studies
Results from other similar studies are of interest, and 
especially comparisons with the commercially available 
active transcutaneous Bone Bridge (Med El). The selected 
comparative studies are chosen with the criteria that both 
tone and speech audiometry are performed in unaided 
and aided conditions and where at least 6 or more sub-
jects are included [Ihler et al., 2014; Rahne and Ehelebe, 
2014; Riss et al., 2014; Eberhard et al., 2016; Gerdes et al., 
2016; Ihler et al., 2016; Schmerber et al., 2017]. Different 
methods have been applied concerning indication for the 
Bone Bridge, number of subjects, tone and speech audi-
ometry, follow-up time, and the presentation of question-
naires. When comparing results from the abovemen-
tioned studies, a general conclusion is that the results are 
similar to this study. Both the BCI and the Bonebridge 
seem to improve tone thresholds and speech perception 
compared to the unaided situation with statistical sup-
port. There also seems to be an established benefit from 
the questionnaire results compared to the unaided situa-
tion. A few studies include comparison with the Bone An-
chored Hearing Aid either on head band or as a percuta-
neous solution (different group of patients) [Gerdes et al., 
2016; Ihler et al., 2016; Schmerber et al., 2017]. Also, in 
these aspects the comparisons with the BCI are similar. 
Surgery is generally without complications, and there are 
no reports of serious skin problems. Among the selected 
comparative studies, the skin in the surgical area is evalu-
ated and described in 3 studies [Ihler et al., 2014; Eber-
hard et al., 2016; Schmerber et al., 2017], where there are 
2 cases with postoperative wound healing resolved using 
only antibiotics in one case, and by both antibiotics and a 
minor surgical intervention in one case.
Adverse Events
After 3 years of use, the patients are satisfied with their 
BCI hearing aid, and no serious adverse event has oc-
curred. Soon after the activation of the audio processor, 
one patient experienced a clicking sound when attaching 
the audio processor and also heard a scratching sound 
when rotating the audio processor in place, but the im-
plant function and the sound quality were not affected 
when the audio processor was in place and in use. It was 
found that the sound phenomena were due to a loose re-
tention magnet within the implanted titanium can. The 
BCI was explanted and a new device was implanted. This 
operation showed that the BCI could easily be removed, 
which is important, e.g. before a vital MRI.
Conclusions
The BCI has been implanted in 16 patients, and in this 
report, 10 patients have completed the 3-year follow-up. 
Warble tone thresholds, SRT, and SRS show improved 
results over the unaided situation at fitting and at every 
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follow-up visit 1, 3, 6, 12, and 36 months after fitting. 
Compared to a Ponto Pro Power on a soft band, there was 
a trend of similar or better results in the majority of the 
parameters including SNR thresholds when using the 
BCI, but without statistically significant differences be-
tween the devices. Three questionnaires were completed, 
and the patients reported on a subjective benefit from the 
BCI intervention as well as use in different listening situ-
ations and in interaction with people around them. The 
results have statistical support in comparison with the 
unaided condition and are stable over time. Sound trans-
mission remained unchanged, indicating good contact to 
the bone and consistent functionality of the whole BCI 
system. The force needed for using the BCI respects skin 
integrity without complications. For indicated patients, 
the BCI is a safe and reliable active transcutaneous BCD.
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